Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders (JAKarta Study)
prof. dr. Rik Schrijvers
20 participants
Nov 21, 2024
INTERVENTIONAL
Conditions
Summary
The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy
Eligibility
Inclusion Criteria3
- Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway.
- Controls (B): participants eligible for inclusion in this study must fall in one of the following categories:
- Healthy controls (without immune-mediated disease)
Exclusion Criteria2
- Children (< 18 years at time of recruitment)
- Persons unable or unwilling to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Blood/serum samples will be collected during routine clinical visits at the time of planned peripheral venous blood sampling. Samples will be processed and either used immediately (flow cytometry-based cell sorting, gDNA extraction, in vitro functional assays, primary cell culture or single-cell applications) or stored for later analysis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07261891